What is the recommended treatment for a peptic ulcer, including H. pylori testing and eradication therapy?

Treatment of Peptic Ulcer Disease

For peptic ulcer disease, test all patients for H. pylori and treat with 14-day bismuth quadruple therapy (BQT) as first-line empiric treatment, while simultaneously addressing NSAID use if present. 1

Initial Management Algorithm

Step 1: H. pylori Testing

• Test all peptic ulcer patients for H. pylori infection using non-invasive methods 2
• Use urea breath test or stool antigen test (most accurate) 3
• Serologic tests are less accurate and cannot confirm eradication 3
• For patients ≥60 years or those with alarm symptoms (bleeding, weight loss, dysphagia), proceed directly to endoscopy 2

Step 2: Address NSAID/Aspirin Use

• Discontinue NSAIDs immediately if possible 4
• If NSAIDs cannot be stopped, treat with proton pump inhibitors (PPIs) 4
• Note: H. pylori infection combined with NSAID use increases bleeding risk more than sixfold 2

Step 3: First-Line H. pylori Eradication

Bismuth Quadruple Therapy (BQT) for 14 days is the preferred first-line treatment 1, 5:

• PPI twice daily
• Bismuth subsalicylate 4 times daily
• Tetracycline 500 mg 4 times daily
• Metronidazole 400-500 mg 3-4 times daily

Why BQT is preferred:

• Effective even with clarithromycin and metronidazole resistance 5
• All three major consensus groups (Toronto, Maastricht V/Florence, ACG) recommend it as first-line 5
• Avoids antibiotic overuse concerns 5

Alternative first-line options (when BQT unavailable) 1:

• Rifabutin triple therapy for 14 days (if no penicillin allergy)
• Vonoprazan dual therapy for 14 days (potassium-competitive acid blocker) 4, 1
• Concomitant non-bismuth quadruple therapy (PPI + amoxicillin + metronidazole + clarithromycin) for 14 days 5

Step 4: Regimens to AVOID as First-Line

Do not use standard triple therapy (PPI + clarithromycin + amoxicillin) empirically due to increasing clarithromycin resistance 6, 2. All three consensus groups restrict this regimen 5.

Treatment Duration

All first-line therapies should be given for 14 days 5. The Toronto Consensus emphasizes that succeeding on the first attempt is critical to avoid retreatment, retesting, increased costs, and negative impacts on gut microbiota 5.

Post-Treatment Confirmation

Universal test-of-cure is recommended 4+ weeks after completing therapy 1:

• Use urea breath test or stool antigen test
• Do not use serology for confirmation 3
• Ensure PPIs are stopped at least 2 weeks before testing

Treatment Failure Management

If H. pylori persists after first-line therapy:

For patients not previously treated with optimized BQT: Use optimized BQT for 14 days 1

For patients who failed optimized BQT: Use rifabutin triple therapy for 14 days 1

Critical caveat: Salvage regimens containing clarithromycin or levofloxacin should only be used if antibiotic susceptibility testing confirms sensitivity 1

Special Populations

Long-term NSAID Users

• Test and treat H. pylori before starting long-term NSAIDs 7
• After eradication, consider PPI co-therapy or switch to celecoxib 2, 4
• H. pylori eradication reduces ulcer risk by 50% in NSAID users 2

Long-term Low-Dose Aspirin (LDA) Users

• Test and treat H. pylori, especially if history of peptic ulcer 7
• Continue PPI or vonoprazan maintenance therapy after eradication in high-risk patients (those on anticoagulants or antiplatelet agents) 7

NSAID-Induced Ulcers (H. pylori-negative)

• Stop NSAIDs and treat with PPIs 4
• If NSAIDs must continue, use PPIs with or without celecoxib 4

Non-H. pylori, Non-NSAID Ulcers

These "idiopathic" ulcers require investigation for other causes 4. Consider:

• Zollinger-Ellison syndrome
• Crohn's disease
• Malignancy
• Other medications (bisphosphonates, SSRIs, anticoagulants) 3

Common Pitfalls

• Do not use clarithromycin-based triple therapy empirically - resistance rates have made this obsolete 6, 1
• Do not rely on serology for test-of-cure - it remains positive after successful eradication 3
• Do not test too early after treatment - wait at least 4 weeks and ensure PPIs stopped 2 weeks prior 1
• In chronic NSAID users, H. pylori eradication alone may be insufficient - continued PPI therapy often needed 7

Emerging Therapies

Vonoprazan (potassium-competitive acid blocker) provides more potent acid suppression than PPIs and is now recommended as an alternative first-line option, particularly effective in Asian populations with genetic polymorphisms affecting PPI metabolism 8, 4, 1.